Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients

J Dermatol. 2003 Jul;30(7):503-9. doi: 10.1111/j.1346-8138.2003.tb00424.x.


Sarcoidosis is a systemic disease of unknown etiology characterized by noncaseating granulomas, consisting mainly of epithelioid cells and multinucleated giant cells derived from monocyte-macrophage lineage cells. Monocytes fall into subpopulations comprising CD14++ CD16-, and CD14+ CD16+ cells, and expansion of the later monocytes has been reported under some pathological conditions. In this study, we examined the immunophenotype of blood monocytes in patients with sarcoidosis using two-color immunofluorescence flow cytometry. In healthy controls CD14+ CD16+ monocytes account for 5.8 +/- 2.8% of monocytes. The percentage of CD14+ CD16+ monocytes was significantly higher (p <0.02) in the sarcoidosis patients (11.8 +/- 4.9%) compared with those in healthy control subjects. The serum ACE levels were significantly correlated with the percentage of CD14+ CD16+ monocytes (p <0.05). In contrast, the percentage was not correlated with purinergic receptor expression of monocytes as estimated by LDH release from BzATP-stimulated monocytes. These findings suggest that CD14+ CD16+ monocytes represent a sensitive marker for the disease activity of sarcoidosis.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Biomarkers / analysis
  • Case-Control Studies
  • Female
  • Humans
  • Lipopolysaccharide Receptors / analysis
  • Lipopolysaccharide Receptors / immunology*
  • Male
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Monocytes / immunology*
  • Monocytes / physiology
  • Probability
  • Receptors, IgG / analysis
  • Receptors, IgG / immunology*
  • Reference Values
  • Sampling Studies
  • Sarcoidosis / immunology*
  • Sarcoidosis / physiopathology
  • Sensitivity and Specificity
  • Severity of Illness Index


  • Biomarkers
  • Lipopolysaccharide Receptors
  • Receptors, IgG